Exelixis, Inc. (NASDAQ:EXEL) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Exelixis, Inc. (NASDAQ:EXEL) have earned a consensus rating of “Moderate Buy” from the nineteen research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and eleven have issued a buy recommendation on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $33.69.

A number of analysts have issued reports on the stock. HC Wainwright lifted their price target on shares of Exelixis from $29.00 to $40.00 and gave the company a “buy” rating in a report on Friday. BMO Capital Markets downgraded Exelixis from an “outperform” rating to a “market perform” rating and boosted their target price for the stock from $36.00 to $40.00 in a research report on Friday, December 20th. UBS Group assumed coverage on Exelixis in a report on Thursday, September 19th. They set a “neutral” rating and a $30.00 price objective on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $34.00 price objective on shares of Exelixis in a report on Wednesday, October 30th. Finally, JMP Securities reissued a “market outperform” rating and issued a $29.00 target price on shares of Exelixis in a report on Friday, October 11th.

Exelixis Stock Up 4.4 %

NASDAQ:EXEL opened at $36.02 on Friday. The stock has a market cap of $10.29 billion, a PE ratio of 23.09, a P/E/G ratio of 0.88 and a beta of 0.53. The business’s 50-day simple moving average is $34.88 and its two-hundred day simple moving average is $28.85. Exelixis has a 52 week low of $20.01 and a 52 week high of $36.97.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 EPS for the quarter, topping analysts’ consensus estimates of $0.36 by $0.04. The company had revenue of $539.50 million for the quarter, compared to analysts’ expectations of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The firm’s revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.10 EPS. Sell-side analysts anticipate that Exelixis will post 1.69 earnings per share for the current fiscal year.

Insider Transactions at Exelixis

In other Exelixis news, EVP Dana Aftab sold 1,162 shares of Exelixis stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $31.40, for a total transaction of $36,486.80. Following the completion of the sale, the executive vice president now directly owns 498,945 shares of the company’s stock, valued at $15,666,873. The trade was a 0.23 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Jeffrey Hessekiel sold 60,000 shares of the company’s stock in a transaction on Friday, November 29th. The stock was sold at an average price of $36.67, for a total value of $2,200,200.00. Following the completion of the sale, the executive vice president now owns 486,059 shares of the company’s stock, valued at $17,823,783.53. This represents a 10.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 314,736 shares of company stock worth $10,849,110. 2.85% of the stock is currently owned by insiders.

Institutional Trading of Exelixis

A number of hedge funds have recently added to or reduced their stakes in the business. V Square Quantitative Management LLC bought a new stake in shares of Exelixis in the 3rd quarter valued at about $30,000. Brooklyn Investment Group bought a new position in Exelixis in the third quarter worth approximately $42,000. Capital Performance Advisors LLP purchased a new stake in Exelixis during the third quarter worth $61,000. Essex Investment Management Co. LLC bought a new stake in Exelixis during the 3rd quarter valued at $74,000. Finally, GAMMA Investing LLC increased its holdings in shares of Exelixis by 50.0% in the 3rd quarter. GAMMA Investing LLC now owns 3,010 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 1,004 shares during the period. 85.27% of the stock is owned by hedge funds and other institutional investors.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.